Cell Genesys, Inc.

Other

Johns Hopkins University

Biosante Pharmaceuticals, Inc.

Gbp IP, LLC

James G McArthur

Salil D Patel

William G Nelson

Thomas L Dull

Margo R Roberts

Dale Ando

Jeno Gyuris

Andrew Simmons

Dale John Talbot

Ryan McGuinness

Ju-Fay Chang

Jonathan Simons

Michael Kelly

Lisa V Tsui

Mitchell H Finer

Michael J Mendez

Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.

Lentiviral vectors featuring liver specific transcriptional enhancer and methods of using same

The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.

Cancer-associated antigens and methods of their identification and use

Liver specific transcriptional enhancer

Lentiviral vectors encoding clotting factors for gene therapy

Polypeptides of adeno-associated virus (AAV) that bind to AAV antibodies or block binding of AAV to mammalian cells are described. Derivatives of peptides can be less immunogenic, enhance binding to cells, render a virus tissue specific and so on. The nucleic acid sequence encoding those derivatives can be incorporated into a capsid encoding sequence to enable a virus to express such a derivative and be less immunogenic, have enhanced transduction efficiency or be tissue specific.

Adeno-associated virus capsid immunologic determinants

Disclosed is a nucleic acid composition consisting essentially of a first nucleic acid sequence encoding a chimeric CDKi protein and a second nudeic acid sequence encoding an adenovirus E4 protein, wherein the first and second nucleic acid sequences are operably linked to at least one regulatory sequence.

Anti-neoplastic compositions and uses thereof

Disclosed are methods for inhibiting angiogenesis using cyclin dependent kinase inhibitors (CDKi) and fusion proteins thereof, recombinant viruses comprising transgenes and nucleic acid sequences encoding the same, and liposomes carrying the same as angiogenesis-inhibiting reagents.

Methods and reagents for inhibiting angiogenesis

Disclosed are methods for using &Dgr;E1/&Dgr;E4 recombinant adenoviruses encoding cyclin dependent kinase inhibitors (CDKi's) as reagents for inhibiting smooth muscle cell proliferation. Also disclosed are recombinant lentiviruses encoding cyclin dependent kinase inhibitors (CDKi's).

Methods and reagents for inhibiting proliferation of smooth muscle cells

Growing community of inventors

San Carlos, CA, United States of America

James G McArthur